Belgium leads call for faster EU medicines access

The European Federation of Pharmaceutical Industries and Associations (EFPIA) is preparing to publish an update on variable rates of access to new medicines in the region.

The research will draw attention to the fact that delays in accessing newly-approved medicines are often attributable to the pricing and reimbursement negotiations that take place on a country-by-country basis.

As the European Commission consults on sweeping changes to the legislative framework for the industry, drugmakers  have argued that this fact has not been sufficiently taken into account.